Elite Pharmaceuticals Inc. logo

Elite Pharmaceuticals Inc. (ELTP)

Market Open
6 Aug, 13:30
OTCQB OTCQB
$
0. 36
-0
-1.3577%
$
409.3M Market Cap
6.76 P/E Ratio
- Div Yield
500 Volume
0 Eps
$ 0.36
Previous Close
Add Transaction
Day Range
0.36 0.36
Year Range
0.33 0.74
Want to track ELTP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?

ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?

Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.

Zacks | 3 weeks ago
Elite Pharmaceuticals Stock Slips Despite Record Fiscal 2026 Earnings

Elite Pharmaceuticals Stock Slips Despite Record Fiscal 2026 Earnings

ELTP delivers record fiscal 2026 results, with stronger profits, improved cash and pipeline progress supporting its expanding generics platform.

Zacks | 1 month ago
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript

Seekingalpha | 1 month ago
Elite Pharmaceuticals Stock Dips Post Q3 Earnings Despite Revenue Jump

Elite Pharmaceuticals Stock Dips Post Q3 Earnings Despite Revenue Jump

ELTP reports surging revenue and profit in third-quarter fiscal 2026, but margin pressure and M&A ambitions steal the spotlight.

Zacks | 5 months ago
ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance

ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance

Elite Pharmaceuticals delivers record second-quarter fiscal 2026 earnings as lisdexamfetamine sales surged, though margins faced competitive pressure.

Zacks | 8 months ago
Elite Pharmaceuticals, Inc. (ELTP) Q2 2026 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (ELTP) Q2 2026 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2026 Earnings Call November 17, 2025 11:30 AM EST Company Participants Nasrat Hakim - Chairman, CEO & President Carter Ward - CFO, Secretary & Treasurer Presentation Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2026 Conference Call. [Operator Instructions] Before management begins speaking, the conference has the following statement.

Seekingalpha | 8 months ago
ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth

ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth

Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.

Zacks | 11 months ago
2 Outperform Rated Small Caps with Recent Pull-backs

2 Outperform Rated Small Caps with Recent Pull-backs

ELTP and TSSI are growth stories with recent material pull-backs.

Zacks | 11 months ago
Elite Pharmaceuticals Stock Dips Despite Record FY25 Revenue Jump

Elite Pharmaceuticals Stock Dips Despite Record FY25 Revenue Jump

ELTP posts record fiscal 2025 revenues and operating income gains, fueled by new launches and expanding generics market share.

Zacks | 1 year ago
Elite Pharmaceuticals, Inc. (ELTP) Q4 2025 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (ELTP) Q4 2025 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2025 Earnings Conference Call July 1, 2025 11:30 AM ET Company Participants Carter J. Ward - CFO, Secretary & Treasurer Nasrat Hakim - Chairman, CEO & President Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call.

Seekingalpha | 1 year ago
ELTP Stock Falls Following Q3 Earnings Decline, Revenue Down Y/Y

ELTP Stock Falls Following Q3 Earnings Decline, Revenue Down Y/Y

Elite Pharmaceuticals' third-quarter fiscal 2025 reports a revenue drop and a net loss. However, delayed shipments impact results.

Zacks | 1 year ago
Two Smaller Companies Worthy of Your "Attention"

Two Smaller Companies Worthy of Your "Attention"

Here we highlight a small cap and a microcap with Zacks Outperform ratings.

Zacks | 1 year ago
Loading...
Load More